...
首页> 外文期刊>Hepatitis Monthly >DRUG-RELATED MUTATIONAL PATTERNS IN HEPATITIS B VIRUS (HBV) REVERSE TRANSCRIPTASE PROTEINS FROM IRANIAN TREATMENT-NAIVE CHRONIC HBV PATIENTS
【24h】

DRUG-RELATED MUTATIONAL PATTERNS IN HEPATITIS B VIRUS (HBV) REVERSE TRANSCRIPTASE PROTEINS FROM IRANIAN TREATMENT-NAIVE CHRONIC HBV PATIENTS

机译:伊朗未经治疗的慢性乙型肝炎患者中乙型肝炎病毒(HBV)逆转录酶蛋白中的药物相关突变模式

获取原文

摘要

Background: Immunomodulators and Nucleotide analogues have been used globally for the dealing of chronic hepatitis B virus (HBV) infection. However, the development of drug resistance is a major limitation to their long-term effectiveness.Objectives: The aim of this study was to characterize the hepatitis B virus reverse transcriptase (RT) protein variations among Iranian chronic HBV carriers who did not receive any antiviral treatments.Materials and Methods: Hepatitis B virus partial RT genes from 325 chronic in active carrier patients were amplified and directly sequenced.Nucleotide/amino acid substitutions were identified compared to the sequences obtained from the database.Results: All strains belonging to genotype D.365 amino-acid substitutions were found. Mutations related to lamivudine, adefovir, telbivudine, and entecavir occurred in (YMDD) 4% (n=13), (SVQ) 17.23% (n=56), (M204I/V+L180M) 2.45% (n=8) and (M204I) 2.76% (n=9) of patients, respectively.Conclusions: RT mutants do occur naturally and could be found in HBV carriers who have never received antiviral therapy. However, mutations related to drug resistance in Iranian treatment-na?ve chronic HBV patients were found to be higher than other studies published formerly. Chronic HBV patients should be monitored closely prior the commencement of therapy to achieve the best regimen option.
机译:背景:免疫调节剂和核苷酸类似物已在全球范围内用于治疗慢性乙型肝炎病毒(HBV)感染。然而,耐药性的发展是其长期有效性的主要限制。目的:本研究的目的是鉴定未接受任何抗病毒治疗的伊朗慢性HBV携带者中的乙型肝炎病毒逆转录酶(RT)蛋白变异特征。材料与方法:扩增并直接测序325例慢性乙型肝炎病毒携带者慢性乙型肝炎病毒的部分RT基因,并对其进行直接测序。与数据库中的序列比较,鉴定出核苷酸/氨基酸取代。结果:所有菌株均属于D基因型。发现365个氨基酸取代。与拉米夫定,阿德福韦,替比夫定和恩替卡韦相关的突变发生在(YMDD)4%(n = 13),(SVQ)17.23%(n = 56),(M204I / V + L180M)2.45%(n = 8)和(M204I)分别为2.76%(n = 9)的患者。结论:RT突变确实是自然发生的,并且可以在从未接受过抗病毒治疗的HBV携带者中发现。然而,发现在伊朗未接受过治疗的慢性HBV患者中,与耐药性相关的突变高于先前发表的其他研究。慢性HBV患者应在治疗开始前密切监测以达到最佳治疗方案。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号